OSLO, NORWAY – 15 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the launch of a microbiome research product for Luminex xMAP® users globally. The GA-map® Discovery reagent kit will offer high-volume precision microbiome analysis to research customers in academia and the pharmaceutical industry. This market is currently witnessing considerable growth, and through this launch, GA will strengthen its position as a pioneer in the microbiome analysis field.
As communicated on October 24, 2023, GA launched the GA-map® Discovery service from its lab in Oslo to research customers within academia and the pharmaceutical industry. Since then, GA has further developed the product, and it is now available as a reagent kit to be used by research labs worldwide. Built on the standardised GA-map® platform, GA-map® Discovery offers comprehensive gut and oral microbiome profiling. The GA-map® platform utilises the unique Luminex xMAP® technology allowing targeted and effective detection of multiple targets simultaneously.
Comprising more than 170 bacteria targets, GA-map® Discovery provides researchers a much-needed tool to search for bacteria profiles / signatures associated with health and disease, as well as validate exploratory research findings. With this launch, GA brings to the market a reagent kit with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiome profiling for the lab.
Sherry Dunbar, Senior Director of Scientific Affairs Programs for Luminex Corp., comments:
“We are excited to see the launch of new products based on Luminex’s xMAP® Technology. This product skillfully combines the high-plex capability of xMAP Technology with GA’s unique method for detection and quantification of microbiome targets. The GA-map® Discovery assay will provide exciting opportunities for accessible microbiome analyses to both new and existing Luminex users worldwide.”
Ronny Hermansen, CEO of Genetic Analysis, comments:
“We are thrilled to introduce the GA-map® Discovery, our latest advancement in microbiome research. This innovative product further solidifies GA’s position in microbiome research, providing an unparalleled tool for both academia and industry. With the microbiome being one of the hottest research areas in clinical medicine and life science today, this high-plex microbiome panel will facilitate researchers in their quest to harness the power of the microbiome.”
Please read the full press release in English: